Efficacy and safety of direct oral anticoagulants in patients undergoing cardioversion for atrial fibrillation: A systematic review and meta-analysis of the literature

International Journal of Cardiology

Volumn 185, Issue , 2015, Pages 72-77

  Dentali, Francesco ^a   Botto, Giovanni Luca ^b   Gianni, Monica ^c   Ambrosino, Pasquale ^d   Di Minno, Matteo Nicola Dario ^e  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

^c Hospital of Tradate   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

Atrial fibrillation; Cardioversion; Direct oral anticoagulants

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DIRECT ORAL ANTICOAGULANT; RIVAROXABAN; UNCLASSIFIED DRUG; VITAMIN K GROUP;

ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; META ANALYSIS; NON VALVULAR ATRIAL FIBRILLATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC EMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; WEIGHTED MEAN INCIDENCE; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; ORAL DRUG ADMINISTRATION; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; EMBOLISM; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; VITAMIN K;

EID: 84928501028     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.03.096     Document Type: Article

References (25)

1. M. Zoni-Berisso, A. Filippi, and M. Landolina Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study) Am. J. Cardiol. 111 2013 705 711
2. L.S. Wann, A.B. Curtis, and K.A. Ellenbogen 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines J. Am. Coll. Cardiol. 57 2011 1330 1337
3. L. Resnekov, and L. McDonald Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electroconversion Br. Heart J. 29 1967 926 936
4. B. Lown, M.G. Perlroth, S. Kaidbey, T. Abe, and D.E. Harken "Cardioversion" of atrial fibrillation: a report on the treatment of 65 episodes in 50 patients N. Engl. J. Med. 269 1963 325 331
5. J.B. Jensen, J.O. Humphries, W.B. Kouwenhoven, and J.R. Jude Electroshock for atrial flutter and atrial fibrillation: follow-up studies on 50 patients JAMA 194 1965 1181 1184
6. C.J. Bjerkelund, and O.M. Orning The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation Am. J. Cardiol. 23 1969 208 216
7. A.Z. Arnold, M.J. Mick, R.P. Mazurek, F.D. Loop, and R.G. Trohman Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter J. Am. Coll. Cardiol. 19 1992 851 855
8. C. Stellbrink, U. Nixdorff, and T. Hofmann Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in cardioversion using enoxaparin (ACE) trial Circulation 109 2004 997 1003
9. A.L. Klein, R.A. Grimm, R.D. Murray, and Assessment of Cardioversion Using Transesophageal Echocardiography Investigators Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation N. Engl. J. Med. 344 2001 1411 1420
10. J.L. Anderson, J.L. Halperin, and N.M. Albert Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J. Am. Coll. Cardiol. 61 2013 1935 1944
11. M.N. Di Minno, A. Russolillo, A. Di Minno, M. Camera, A. Parolari, and E. Tremoli Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients Expert. Opin. Emerg. Drugs 18 2013 9 23
12. F. Dentali, N. Riva, M. Crowther, A.G. Turpie, G.Y. Lip, and W. Ageno Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature Circulation 126 2012 2381 2391
13. C.T. Ruff, R.P. Giugliano, and E. Braunwald Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 2014 955 962
14. S. Schulman, C. Kearon, and Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J. Thromb. Haemost. 3 2005 692 694
15. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, and PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med. 6 2009 e1000097
16. J.A. Sterne, M. Egger, and G.D. Smith Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis BMJ 323 2001 101 105
17. R. Nagarakanti, M.D. Ezekowitz, and J. Oldgren Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion Circulation 123 2011 131 136
18. J.P. Piccini, S.R. Stevens, and Y. Lokhnygina Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial J. Am. Coll. Cardiol. 61 2013 1998 2006
19. G. Flaker, R.D. Lopes, and S.M. Al-Khatib Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) J. Am. Coll. Cardiol. 63 2014 1082 1087
20. R. Cappato, M.D. Ezekowitz, and A.L. Klein Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation Eur. Heart J. 35 2014 3346 3355
21. A.L. Klein, R.A. Grimm, and R.D. Murray Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation N. Engl. J. Med. 344 2001 1411 1420
22. D.M. Weinberg, and J. Mancini Anticoagulation for cardioversion of atrial fibrillation Am. J. Cardiol. 63 1989 745 746
23. A. Yadlapati, C. Groh, and R. Passman Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter Am. J. Cardiol. 113 2014 1362 1363
24. https://clinicaltrials.gov/ct2/show/NCT02072434?term=cardioversion+edoxaban&rank=1
25. https://clinicaltrials.gov/ct2/show/NCT01593150?term=cardioversion+apixaban&rank=1